Atezolizumab in advanced non-small cell lung cancer

doi:10.21037/jtd.2017.09.73

Editorial

. 2017 Oct;9(10):3603-3606.

doi: 10.21037/jtd.2017.09.73.

Atezolizumab in advanced non-small cell lung cancer

Marius Ilie^{1

2

3}, Paul Hofman^{1

2

3}

Affiliations

¹ Université Côte d'Azur, University Hospital Federation OncoAge, Laboratory of Clinical and Experimental Pathology, Hôpital Pasteur, Nice, France.
² Université Côte d'Azur, Institute for Research on Cancer and Ageing, Nice (IR-CAN), Inserm U1081 and UMR CNRS 7284, Nice, France.
³ Université Côte d'Azur, University Hospital Federation OncoAge, Hospital-Related Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France.

PMID: 29268352
PMCID: PMC5723868
DOI: 10.21037/jtd.2017.09.73

Editorial

Atezolizumab in advanced non-small cell lung cancer

Marius Ilie et al. J Thorac Dis. 2017 Oct.

. 2017 Oct;9(10):3603-3606.

doi: 10.21037/jtd.2017.09.73.

Authors

Marius Ilie^{1

2

3}, Paul Hofman^{1

2

3}

Affiliations

¹ Université Côte d'Azur, University Hospital Federation OncoAge, Laboratory of Clinical and Experimental Pathology, Hôpital Pasteur, Nice, France.
² Université Côte d'Azur, Institute for Research on Cancer and Ageing, Nice (IR-CAN), Inserm U1081 and UMR CNRS 7284, Nice, France.
³ Université Côte d'Azur, University Hospital Federation OncoAge, Hospital-Related Biobank (BB-0033-00025), Hôpital Pasteur, Nice, France.

PMID: 29268352
PMCID: PMC5723868
DOI: 10.21037/jtd.2017.09.73

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Paul Hofman is a member of different industrial scientific advisory boards (Roche, AstraZeneca, Novartis, Bristol-Myers Squibb, Pfizer, Qiagen, Janssen, Biocartis) for which he receives honorarium. Marius Ilié has no conflicts of interest to declare.

Comment on

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. Peters S, et al. J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13. J Clin Oncol. 2017. PMID: 28609226 Free PMC article. Clinical Trial.

Cited by

Recent advances in non-small cell lung cancer targeted therapy; an update review.
Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Araghi M, et al. Cancer Cell Int. 2023 Aug 11;23(1):162. doi: 10.1186/s12935-023-02990-y. Cancer Cell Int. 2023. PMID: 37568193 Free PMC article. Review.
A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.
Panahi Y, Mohammadzadeh AH, Behnam B, Orafai HM, Jamialahmadi T, Sahebkar A. Panahi Y, et al. Adv Exp Med Biol. 2021;1286:49-64. doi: 10.1007/978-3-030-55035-6_3. Adv Exp Med Biol. 2021. PMID: 33725344 Review.
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.
Afzal MZ, Dragnev K, Sarwar T, Shirai K. Afzal MZ, et al. Lung Cancer Manag. 2019 May 7;8(2):LMT11. doi: 10.2217/lmt-2018-0016. eCollection 2019 Oct. Lung Cancer Manag. 2019. PMID: 31645894 Free PMC article.
Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer.
Tone M, Izumo T, Awano N, Kuse N, Inomata M, Jo T, Yoshimura H, Miyamoto S, Kunitoh H. Tone M, et al. Lung Cancer Manag. 2019 May 9;4(6):LMT12. doi: 10.2217/lmt-2019-0001. eCollection 2019 Oct. Lung Cancer Manag. 2019. PMID: 31645892 Free PMC article.
Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS. Min Lee CK, et al. J Am Acad Dermatol. 2018 Dec;79(6):1047-1052. doi: 10.1016/j.jaad.2018.05.035. Epub 2018 May 29. J Am Acad Dermatol. 2018. PMID: 29857011 Free PMC article.

References

1. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7. 10.1038/nature14011 - DOI - PMC - PubMed
1. Peters S, Gettinger S, Johnson ML, et al. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017;35:2781-9. 10.1200/JCO.2016.71.9476 - DOI - PMC - PubMed
1. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46. 10.1016/S0140-6736(16)00587-0 - DOI - PubMed
1. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65. 10.1016/S0140-6736(16)32517-X - DOI - PMC - PubMed
1. Hanna N, Johnson D, Temin S, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;JCO2017746065. - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7. 10.1038/nature14011 - DOI - PMC - PubMed

[2] Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7. 10.1038/nature14011 - DOI - PMC - PubMed

[3] Peters S, Gettinger S, Johnson ML, et al. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017;35:2781-9. 10.1200/JCO.2016.71.9476 - DOI - PMC - PubMed

[4] Peters S, Gettinger S, Johnson ML, et al. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017;35:2781-9. 10.1200/JCO.2016.71.9476 - DOI - PMC - PubMed

[5] Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46. 10.1016/S0140-6736(16)00587-0 - DOI - PubMed

[6] Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46. 10.1016/S0140-6736(16)00587-0 - DOI - PubMed

[7] Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65. 10.1016/S0140-6736(16)32517-X - DOI - PMC - PubMed

[8] Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65. 10.1016/S0140-6736(16)32517-X - DOI - PMC - PubMed

[9] Hanna N, Johnson D, Temin S, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;JCO2017746065. - PubMed

[10] Hanna N, Johnson D, Temin S, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;JCO2017746065. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Atezolizumab in advanced non-small cell lung cancer

Affiliations

Atezolizumab in advanced non-small cell lung cancer

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources